UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells.

doi:10.1002/1878-0261.12372

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells.

Molecular oncology - 1 Oct 2018

Sane Sanam, Hafner Andre, Srinivasan Rekha, Masood Daniall, Slunecka John L, Noldner Collin J, Hanson Alex D, Kruisselbrink Taylor, Wang Xuejun, Wang Yiyang, Yin Jun, Rezvani Khosrow

Abstract excerpt

Overexpression of oncoproteins is a major cause of treatment failure using current chemotherapeutic drugs. Drug-induced degradation of oncoproteins is feasible and can improve clinical outcomes in diverse types of cancers. Mortalin-2 (mot-2) is a dominant oncoprotein in several tumors, including colorectal cancer (CRC). In addition to inactivating the p53 tumor suppressor protein, mot-2 enhances tumor cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chaperonin 60
Share to Colon

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Haploinsufficiency

Share to HSP70 Heat-Shock Proteins

Share to Multiprotein Complexes

Share to Ubiquitin

Share to Ubiquitination

Share to Ubiquitins

Source

Open in PubMed Open full text

Identifiers

PMID: 30107089
DOI: 10.1002/1878-0261.12372
PMCID: PMC6166003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.